

39. Hall, S. S. *The Claritin Effect; Prescription for Profit*. The New York Times, March 11, 2001.
40. Zhang, Y. F.; Chen, X. Y.; Zhong, D. F.; Dong, Y. M. Pharmacokinetics of Loratadine and its Active Metabolite Descarboethoxyloratadine in Healthy Chinese Subjects. *Acta Pharmacol. Sin.* **2003**, *24* (7), 715–718.
41. Smith, A. *Big Pharma Teaches Old Drugs New Tricks: Drugmakers Hunt for New Patents on Old Blockbusters to Try and Postpone the Inevitable: Generic Competition*. CNNMoney.com, March 21, 2007.
42. Hori, G.; Gold, S. Demerol in Surgery and Obstetrics. *Can. Med. Assoc. J.* **1944**, *51* (6), 509–517.
43. Ziering, A.; Lee, J. Piperidine Derivatives; 1,3-dialkyl-4-aryl-4-acyloxy piperidines. *J. Org. Chem.* **1947**, *12* (6), 911–914.
44. a. In *The Case of the Frozen Addicts: How the Solution of a Medical Mystery Revolutionized the Understanding of Parkinson's Disease*; Langston, J. W., Palfreman, J., Eds. IOS Press: Amsterdam, The Netherlands, 2014.
b. Langston, J. W.; Ballard, P.; Tetrud, J. W.; Irwin, I. Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis. *Science* **1983**, *219* (4587), 979–980.
45. a. In *Goodman and Gilman's the Pharmacological Basis of Therapeutics*, 9th ed.; Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W., Goodman, A. G., Eds. McGraw-Hill: New York, NY, 1996; p 542.
b. Chan, K.; Kendall, M. J.; Mitchard, M. Quantitative Gas-Liquid Chromatographic Method for the Determination of Pethidine and its Metabolites, Norpethidine and Pethidine N-oxide in Human Biological Fluids. *J. Chromatogr.* **1974**, *89* (2), 169–176.
46. a. Pifl, C.; Giros, B.; Caron, M. G. Dopamine Transporter Expression Confers Cytotoxicity to Low Doses of the Parkinsonism-inducing Neurotoxin 1-methyl-4-phenylpyridinium. *J. Neurosci.* **1993**, *13* (10), 4246–4253.
b. Burns, R. S.; Markey, S. P.; Phillips, J. M.; Chiueh, C. C. The Neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the Monkey and Man. *Can. J. Neurol. Sci.* **1984**, *11* (1), S166–S168.
c. Markey, S. P.; Johannessen, J. N.; Chiueh, C. C.; Burns, R. S.; Herkenham, M. A. Intraneuronal Generation of a Pyridinium Metabolite May Cause Drug-induced Parkinsonism. *Nature* **1984**, *311* (5985), 464–467.
47. a. Langston, J. W.; Forno, L. S.; Rebert, C. S.; Irwin, I. Selective Nigral Toxicity after Systemic Administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the Squirrel Monkey. *Brain Res.* **1984**, *292* (2), 390–394.
b. Irwin, I.; Langston, J. W. Selective Accumulation of MPP+ in the Substantia Nigra: A Key to Neurotoxicity? *Life Sci.* **1985**, *36* (3), 207–212.
48. Fava, M.; Rush, A. J.; Thase, M. E.; Clayton, A.; Stahl, S. M.; Pradko, J. F.; Johnston, J. A. 15 Years of Clinical Experience with Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL. *Prim. Care Companion J. Clin. Psychiatry* **2005**, *7* (3), 106–113.
49. Dunner, D. L.; Zisook, S.; Billow, A. A.; Batey, S. R.; Johnston, J. A.; Ascher, J. A. A Prospective Safety Surveillance Study for Bupropion Sustained-Release in the Treatment of Depression. *J. Clin. Psychiatry* **1998**, *59* (7), 366–373.
50. Jefferson, W. J.; Pradko, J. F.; Muir, K. T. Bupropion for Major Depressive Disorder: Pharmacokinetic and Formulation Considerations. *Clin. Ther.* **2005**, *27* (11), 1685–1695.
51. Lange, K. W.; Reichl, S.; Lange, K. M.; Tucha, L.; Tucha, O. The History of Attention Deficit Hyperactivity Disorder. *ADHD Atten. Def. Hyp. Disord.* **2010**, *2* (4), 241–255.
52. Concerta® (Methylphenidate HCl) Extended Release Tablet Prescription Package Insert.
53. Dubois, R. N.; Abramson, S. B.; Crofford, L.; Gupta, R. A.; Simon, L.; Van De Putte, L. B. A.; Lipsky, P. E. Cyclooxygenase in Biology and Disease. *FASEB J.* **1998**, *12* (12), 1063–1073.
54. Young D. A.; O'Banion M. K.; Winn V. D. Method of Inhibiting Prostaglandin Synthesis in a Human Host. US 6048850, **2000**.